DexCom Q1 revenue $1.04B (+12% YoY); guides FY25 gross margin ~62% (down); announces $750M buyback

DEXCOM INC

2025-Q1 EPS reported $0.27 revenue$1,036,000,000

GAAP net income $105.4M ($0.27 diluted EPS) vs $146.4M ($0.36) YoY; non-GAAP EPS $0.32 flat.
Revenue $1.036B (+12% reported, +14% organic); US +15%, intl +7% (organic +12%).
FY25 guidance: revenue $4.6B (+14%), non-GAAP gross margin ~62% (cut from prior), op margin ~21%, EBITDA margin ~30%.
Board authorized $750M share repurchase program through June 30, 2026.
Post-quarter FDA clearance for G7 15-day system; expanded PBM coverage and Stelo on Amazon.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.